| You are here: Home: BCU 5|2002: I Craig Henderson, MD - Select Publications
Select publications
Adjuvant use of aromatase inhibitors for postmenopausal,
ER-positive patients
Pharmacokinetics of anastrozole and tamoxifen alone and
in combination during adjuvant endocrine therapy for early breast
cancer in postmenopausal women: A subprotocol of the "Arimidex®
and Tamoxifen Alone or in Combination" (ATAC) trial. Br
J Cancer 2001;85(3):317-324. Abstract
Baum M. The ATAC (Arimidex, Tamoxifen, Alone or in Combination)
adjuvant breast cancer trial in postmenopausal women. Breast
Cancer Res Treat 2001;69(3):Abstract
8.
Baum M et al. Sequential power calculations in a recruitment
phase of a multicentre trial — the experience of the 'Arimidex
(anastrozole), tamoxifen alone or in combination' (ATAC) study.
Proc ASCO 2002;Abstract
185.
Brodie A. Aromatase inhibitors in breast cancer. Trends
Endocr Metab 2002;13(2):61-65. Abstract
Buzdar AU. Anastrozole (Arimidex) —- an aromatase
inhibitor for the adjuvant setting? Br J Cancer 2001;85(2
suppl):6-10. Abstract
Duffy SRG et al. The ATAC ('Arimidex,' tamoxifen, alone
or in combination) early breast cancer (EBC) trial in postmenopausal
(PM) patients: Endometrial subprotocol results. Proc ASCO
2002;Abstract
158.
Fallowfield L et al. Assessing the quality of life (QOL)
of postmenopausal (PM) women randomized into the ATAC ('Arimidex,'
tamoxifen, alone or in combination) adjuvant breast cancer (BC)
trial. Proc ASCO 2002;Abstract
159.
Goss PE. Preliminary data from ongoing adjuvant aromatase
inhibitor trials. Clin Cancer Res 2001;7(12 suppl):4397s-4401s.
Abstract
Howell A. Future use of selective estrogen receptor modulators
and aromatase inhibitors. Clin Cancer Res 2001;7(12 suppl):4402s-4410s.
Abstract
Howell A et al. Where do selective estrogen receptor modulators
(SERMs) and aromatase inhibitors (AIs) now fit into breast cancer
treatment algorithms?J Steroid Biochem Mol Biol 2001;79:227-237.
Abstract
Ingle JN. Aromatase inhibition and antiestrogen therapy
in early breast cancer treatment and chemoprevention. Oncology
(Huntingt) 2001;15:28-34. Abstract
Johnson PE, Buzdar A. Are differences in the available
aromatase inhibitors and inactivators significant? Clin
Cancer Res 2001;7(12 Suppl):4360s-4368s. Abstract
Mamounas EP. Adjuvant exemestane therapy after 5 years
of tamoxifen: Rationale for the NSABP B-33 trial. Oncology
(Huntingt) 2001;15(5 Suppl 7):35-39. Abstract
Nicholls H. Aromatase inhibitors continue their ATAC on
tamoxifen. Trends Mol Med 2002;8(4):S12-3. Abstract
Ragaz J. Adjuvant trials of aromatase inhibitors: Determining
the future landscape of adjuvant endocrine therapy. J Steroid
Biochem Mol Biol 2001;79:133-141. Abstract
Menopause and the endocrine effects of adjuvant
therapy on pre- and postmenopausal patients
Bhatavdekar JM et al. Endocrine function in premenopausal
and postmenopausal advanced breast cancer patients treated with
CMF or tamoxifen. Neoplasma 1992;39:123-7. Abstract
Bianco AR et al. Prognostic role of amenorrhea induced
by adjuvant chemotherapy in premenopausal patients with early breast
cancer. Br J Cancer 1991;63:799-803. Abstract
Bines J et al. Ovarian function in premenopausal women
treated with adjuvant chemotherapy for breast cancer. J
Clin Oncol 1996;14:1718-29. Abstract
Braverman AS et al. Premenopausal serum estradiol (E2)
levels may persist after chemotherapy (CT)- induced amenorrhea in
breast cancer (BC). Proc ASCO 2002;Abstract
164.
Burger HG. The endocrinology of the menopause.
J Steroid Biochem Mol Biol 1999;69(1-6):31-5. Abstract
Burger HG. The menopause: When it is all over or is it?
Aust N Z J Obstet Gynaecol 1994;34(3):293-5. Abstract
Burger HG et al. Hormonal changes in the menopause transition.
Recent Prog Horm Res 2002;57:257- 75. Abstract
Burger HG et al. Prospectively measured levels of serum
follicle-stimulating hormone, estradiol, and the dimeric inhibins
during the menopausal transition in a population-based cohort of
women. J Clin Endocrinol Metab 1999;84(11):4025-30. Abstract
Chakravarti S et al. Hormonal profiles after the menopause.
Br Med J 1976;2(6039):784-7. Abstract
Collichio F, Pandya K. Amenorrhea following chemotherapy
for breast cancer: Effect on disease-free survival. Oncology
(Huntingt) 1994;8:45-52. Abstract
Del Mastro L et al. Amenorrhea induced by adjuvant chemotherapy
in early breast cancer patients: Prognostic role and clinical implications.
Breast Cancer Res Treat 1997;43:183-90. Abstract
Goldhirsch A et al. The magnitude of endocrine effects
of adjuvant chemotherapy for premenopausal breast cancer patients.
The International Breast Cancer Study Group. Ann Oncol
1990;1:183-8. Abstract
Johannes CB, Crawford SL. Menstrual bleeding, hormones,
and the menopausal transition. Semin Reprod Endocrinol
1999;17(4):299-309. Abstract
Kalantaridou SN, Nelson LM. Premature ovarian failure
is not premature menopause. Ann N Y Acad Sci 2000;900:393-402.
Abstract
Lower EE et al. The risk of premature menopause induced
by chemotherapy for early breast cancer. J Womens Health
Gend Based Med 1999;8:949-54. Abstract
Pagani O et al. Prognostic impact of amenorrhoea after
adjuvant chemotherapy in premenopausal breast cancer patients with
axillary node involvement: Results of the International Breast Cancer
Study Group (IBCSG) Trial VI. Eur J Cancer 1998;34:632-40.
Abstract
Poikonen P et al. Prognostic effect of amenorrhoea and
elevated serum gonadotropin levels induced by adjuvant chemotherapy
in premenopausal node-positive breast cancer patients.
Eur J Cancer 2000;36:43-8. Abstract
Sherman BM et al. The menopausal transition: Analysis
of LH, FSH, estradiol, and progesterone concentrations during menstrual
cycles of older women. J Clin Endocrinol Metab 1976;42(4):629-36.
Abstract
Toma S et al. Chemotherapy-induced amenorrhea and other
clinical and pathological parameters in the prognosis of breast
cancer patients. J Chemother 1992;4:321-5. Abstract
Utian WH. Ovarian function, therapy-oriented definition
of menopause and climacteric. Exp Gerontol 1994;29(3-4):245-51.
Abstract
|
